Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10,050 | 14 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $10,050 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,050 | 14 | F. Hoffmann-La Roche AG ($10,050) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $860.05 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $764.68 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $669.89 | Research |
| Study: 2L ASCT eligible study in DLBCL glofit R ICE | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $562.85 | Research |
| Study: 2L ASCT eligible study in DLBCL glofit R ICE | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $363.00 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $263.00 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $242.69 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $230.07 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $226.42 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $218.70 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $133.50 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $133.50 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $5,277.27 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $104.05 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | F. Hoffmann-La Roche AG | $8,817 | 12 |
| 2L ASCT eligible study in DLBCL glofit R ICE | F. Hoffmann-La Roche AG | $1,233 | 2 |
About Dr. Stephen Simko, MD
Dr. Stephen Simko, MD is a Pediatrics healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1861539124.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Simko, MD has received a total of $10,050 in payments from pharmaceutical and medical device companies, with $10,050 received in 2024. These payments were reported across 14 transactions from 1 company. The most common payment nature is "" ($10,050).
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Hematology-Oncology
- Location Palo Alto, CA
- Active Since 01/30/2007
- Last Updated 04/16/2024
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1861539124
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Palo Alto
Carlos Milla, Md, MD
Pediatrics — Payments: $135,086
Paul Grimm, Md, MD
Pediatrics — Payments: $115,205
Janene Fuerch, Md, MD
Pediatrics — Payments: $106,632
Jennifer Frankovich, Md, MD
Pediatrics — Payments: $99,067
Crystal Mackall, Md, MD
Pediatrics — Payments: $56,852
Jennifer O'malley, Md, Phd, MD, PHD
Pediatrics — Payments: $46,160